Evidence map›Paper›PMID 38669097›Full record

ReviewACS synthetic biology2024

Perspectives on Genetically Engineered Microorganisms and Their Regulation in the United States.

Arik Shams, Alexandria Fischer, Anastasia Bodnar, Melinda Kliegman

Erratum issuedAbstract readReview
In one paragraph

Review in ACS synthetic biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Recent trends in microbial production of alkanes.World journal of microbiology & biotechnology · 2025
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Arik ShamsKavli Center for Ethics, Science, and the Public, University of California─Berkeley, Berkeley, California 94720, United States.ORCID 0000-0002-0151-0593
Alexandria FischerUnited States Department of Agriculture, Washington, D.C. 20250, United States.
Anastasia BodnarUnited States Department of Agriculture, Washington, D.C. 20250, United States.
Melinda KliegmanInnovative Genomics Institute, University of California─Berkeley, Berkeley, California 94720, United States.ORCID 0000-0002-9710-795X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetically engineered microorganisms (GEMs) represent a new paradigm in our ability to address the needs of a growing, changing world. GEMs are being used in agriculture, food production and additives, manufacturing, commodity and noncommodity products, environmental remediation, etc., with even more applications in the pipeline. Along with modern advances in genome-manipulating technologies, new manufacturing processes, markets, and attitudes are driving a boom in more products that contain or are derived from GEMs. Consequentially, researchers and developers are poised to interact with biotechnology regulatory policies that have been in effect for decades, but which are out of pace with rapidly changing scientific advances and knowledge. In the United States, biotechnology is regulated by multiple agencies with overlapping responsibilities. This poses a challenge for both developers and regulators to simultaneously allow new innovation and products into the market while also ensuring their safety and efficacy for the public and environment. This article attempts to highlight the various factors that interact between regulatory policy and development of GEMs in the United States, with perspectives from both regulators and developers. We present insights from a 2022 workshop hosted at the University of California, Berkeley that convened regulators from U.S. regulatory agencies and industry developers of various GEMs and GEM-derived products. We highlight several new biotechnologies and applications that are driving innovation in this space, and how regulatory agencies evaluate and assess these products according to current policies. Additionally, we describe recent updates to regulations that incorporate new technology and knowledge and how they can adapt further to effectively continue regulating for the future.

Indexed as

BiotechnologyGenetic EngineeringMicroorganisms, Genetically-ModifiedUnited Statesbiotechnologygenetic engineeringmicroorganismsregulationsscience policysynthetic biology

Identifiers

PMID38669097
PMCPMC11106772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.